FDA Panel Rejects Pimavanserin for Alzheimer’s Psychosis

A US Food and Drug Administration (FDA) advisory panel has rejected the atypical antipsychotic pimavanserin (Nuplazid, Acadia Pharmaceuticals) for the treatment of Alzheimer’s disease psychosis (ADP). In a 9-3 vote, the Psychopharmacologic Drugs Advisory Committee (PDAC) found that the drug’s manufacturer failed to offer convincing evidence of its efficacy in patients with ADP. Today’s rejection … Read more

Triptans in Pregnancy and ADHD in Kids: New Reassuring Data

Triptan use during pregnancy does not increase the risk for attention-deficit/hyperactivity disorder (ADHD) in offspring, new research suggests. Hedvig Nordeng, PhD “The findings should satisfy women who need to take this class of drugs during pregnancy,” study author Hedvig Nordeng, PhD, professor and head of the Pharmacoepidemiology and Drug Safety Research Group at the University … Read more

Cannabis on Par With Opioids for Pain Relief, Study Suggests

Cannabis-based products may control chronic pain as effectively as opioids, but adverse effects are common, and long-term safety remains unknown, according to a new study. Several other systematic reviews have recently evaluated cannabinoids for treating chronic pain, but the new study’s methodology was “distinct” in “important ways,” leading to “conclusions that differ from other reviews,” … Read more

High-Dose Antipsychotics Effective in Refractory Schizophrenia

NEW ORLEANS – Patients with severe schizophrenia who fail to respond to treatment with standard doses of second-generation antipsychotics show significant improvement with – and tolerance of – higher maintenance doses of the drugs, new research shows. Dr Juan Jose Fernandez-Miranda The use of [higher doses of] long-acting injectable second-generation antipsychotics shows improvement not only … Read more

The Stigma Associated With Mental Illness and Antidepressants

The good, the bad, and the ugly. It’s easy to talk about the good, but when it comes to having real conversations about mental health, it’s sometimes an uphill battle. We see so much about mental well-being, services, and hotlines available for those in need. In fact, it’s almost expected for schools and workplaces to … Read more

A Little-Known Option for Depression

Standard therapies for depression are antidepressants and psychotherapy. In particularly severe cases, electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) may also be indicated. VNS is an approved, effective, well-tolerated, long-term therapy for chronic and therapy-resistant depression, write Christine Reif-Leonhardt, MD, and her team of researchers from the University Hospital Frankfurt am Main, Germany, in … Read more

Methylphenidate Is Overprescribed to Children in France

The prevalence of attention-deficit/hyperactivity disorder (ADHD) is difficult to evaluate, and the diagnosis is based primarily on clinical criteria. In 2008, a French study estimated the prevalence to be between 3.5% and 5.6%, but the study’s design was questionable. Treatment of this disorder consists first and foremost in educational, social, and psychotherapeutic management. Only if … Read more